Kate Therapeutics
Delayne Di Gangi is a Research Associate II at Kate Therapeutics, bringing experience from previous roles at IconOVir Bio, Astellas Research Institute of America LLC, RoosterBio Inc., and various research assistant positions at Clemson University. They have a background in biomedical engineering and have worked on projects involving cell cultures, tissue engineering, and synthetic biology. They have also interned at Ricoh Company, Ltd. and conducted research at Northwestern University and The University of Tokyo. They hold a High School Diploma from Marian Central Catholic High School.
Kate Therapeutics
Kate Therapeutics (KateTx) is a patient-focused biotechnology company developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined muscle and heart diseases. The company is applying novel technology platforms that directly address the key limitations of current gene therapies, including tissue-specific delivery and gene regulation. These breakthroughs have the potential to improve the efficacy and safety of gene therapies and enable the pursuit of a broader set of targets that are otherwise difficult to drug with current technologies.